Ozempic, also known as semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist used to improve glycemic control in adults with type 2 diabetes. According to the drug's prescribing information, Ozempic can impact meal portions through its effects on appetite regulation and gastric emptying [1].

Clinical studies have shown that GLP-1 receptor agonists, like Ozempic, can lead to reduced food intake and body weight [2]. This is partly due to delayed gastric emptying, which creates a feeling of fullness and reduces appetite [3]. As a result, individuals taking Ozempic may find themselves consuming smaller meal portions naturally.

However, it is essential to note that Ozempic is not a weight-loss drug and should not be used primarily for this purpose. Patients should follow a healthy diet and exercise plan as prescribed by their healthcare provider [1].

In summary, Ozempic can influence meal portions by affecting appetite regulation and gastric emptying, leading to reduced food intake and body weight.

Sources:

1. Novo Nordisk. (2021). Ozempic (semaglutide) injection, for subcutaneous use [Prescribing Information]. Retrieved from <https://www.novo-pi.com/ozempic.pdf>
2. Halford, J. C. G., & Harrold, J. A. (2019). Glucagon-like peptide-1 receptor agonists for the treatment of obesity. Obesity reviews, 20(1), 3-15. doi: 10.1111/obr.12784
3. Drugs.com. (2021). Ozempic. Retrieved from <https://www.drugs.com/ozempic.html>
4. DrugPatentWatch.com. (2021). Ozempic (semaglutide) Patent, Legal, and FDA Information. Retrieved from <https://www.drugpatentwatch.com/drugs/ozempic>